Digital Breast Tomosynthesis Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Global Digital Breast Tomosynthesis Equipment Market was valued at USD 3.02 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 9.89% through 2029. The Global Digital Breast Tomosynthesis Equipment Market is a dynamic landscape characterized by innovation, technological advancements, and a growing emphasis on early detection and precise diagnosis of breast cancer. Breast tomosynthesis, also known as 3D mammography, has revolutionized breast imaging by offering improved visualization of breast tissue compared to traditional 2D mammography. This market has witnessed significant growth driven by factors such as increasing incidences of breast cancer, rising awareness about the importance of early detection, and advancements in imaging technology. As healthcare systems worldwide prioritize preventive care and personalized treatment approaches, digital breast tomosynthesis has emerged as a crucial tool in the arsenal against breast cancer. The market encompasses a wide range of equipment, including digital breast tomosynthesis systems, software solutions for image processing and analysis, and associated accessories. Key players in this market are continuously investing in research and development to enhance the capabilities of their products, focusing on features like improved image resolution, faster scan times, and enhanced workflow efficiency.

Key Market Drivers

Rising Incidence of Breast Cancer

The rising incidence of breast cancer is a significant driver behind the growth of the global digital breast tomosynthesis equipment market. Breast cancer remains one of the most common types of cancer among women worldwide, with millions of new cases diagnosed each year. Factors such as aging populations, lifestyle changes, and increased awareness leading to more screenings contribute to the rising incidence rates.

As the number of breast cancer cases continues to climb, there is a growing emphasis on early detection as a crucial factor in improving survival rates and treatment outcomes. Digital breast tomosynthesis (DBT) offers several advantages over traditional 2D mammography, including improved sensitivity and specificity in detecting breast abnormalities. The ability of DBT to provide three-dimensional images of breast tissue helps radiologists identify lesions more accurately, reducing false-positive and false-negative results.

Healthcare providers are increasingly turning to DBT equipment to enhance their breast cancer screening and diagnostic capabilities. By adopting DBT technology, healthcare facilities can offer their patients a more advanced and comprehensive screening experience, leading to earlier detection of breast cancer and potentially better patient outcomes. Regulatory bodies and healthcare organizations are recognizing the clinical benefits of DBT and incorporating it into breast cancer screening guidelines and recommendations. This growing acceptance and endorsement of DBT as a preferred imaging modality for breast cancer detection further drive its adoption in healthcare settings worldwide.

The rising incidence of breast cancer also underscores the need for continuous innovation and improvement in breast imaging technology. Manufacturers are investing in research and development to enhance the performance and capabilities of digital breast tomosynthesis equipment, focusing on areas such as image resolution, workflow efficiency, and patient comfort. These advancements not only improve the diagnostic accuracy of DBT but also make it more accessible and user-friendly for healthcare providers and patients alike.

Growing Emphasis on Early Detection and Screening Programs

The growing emphasis on early detection and screening programs is a key driver propelling the expansion of the global digital breast tomosynthesis equipment market. Early detection plays a critical role in improving treatment outcomes and survival rates for breast cancer patients, making it a primary focus for healthcare systems worldwide. Screening programs aim to identify breast abnormalities at their earliest stages, when treatment options are most effective, and chances of survival are highest.

Digital breast tomosynthesis (DBT) has emerged as a powerful tool in breast cancer screening due to its ability to provide three-dimensional images of breast tissue with enhanced clarity and detail compared to traditional 2D mammography. The superior sensitivity and specificity of DBT in detecting breast abnormalities contribute to its increasing adoption in screening programs globally. Healthcare organizations, advocacy groups, and governmental agencies are actively promoting breast cancer screening initiatives to raise awareness and encourage early detection among women. These programs often incorporate digital breast tomosynthesis technology as part of their screening protocols, offering patients access to advanced imaging modalities that improve the accuracy and reliability of breast cancer detection.

The integration of DBT into organized screening programs and routine clinical practice has become more widespread as healthcare providers recognize the clinical benefits of this technology. Digital breast tomosynthesis enables radiologists to detect smaller lesions, identify architectural distortions, and reduce false-positive and false-negative findings, leading to more accurate diagnoses and better patient outcomes. In addition to traditional screening programs, there is a growing trend towards personalized screening approaches that take into account individual risk factors and preferences. Digital breast tomosynthesis equipment allows for tailored screening protocols based on a patient's breast density, family history, genetic predisposition, and other relevant factors, optimizing the effectiveness of screening efforts and minimizing unnecessary interventions.

Technological Advancements in Imaging Technology

Technological advancements in imaging technology are playing a pivotal role in driving the growth of the global digital breast tomosynthesis equipment market. As the field of medical imaging continues to evolve, manufacturers are constantly innovating to enhance the capabilities and performance of digital breast tomosynthesis (DBT) equipment, leading to improved diagnostic accuracy and patient outcomes. One of the key technological advancements driving the adoption of digital breast tomosynthesis equipment is the development of higher-resolution imaging sensors and detectors. These advancements enable DBT systems to capture detailed three-dimensional images of breast tissue with greater clarity and precision, enhancing the ability of radiologists to detect subtle abnormalities and lesions.

Advancements in image reconstruction algorithms and processing software have significantly improved the quality of DBT images while reducing noise and artifacts. Sophisticated reconstruction techniques such as iterative reconstruction and model-based algorithms enhance image resolution and contrast, enabling more accurate interpretation of breast images and reducing the likelihood of false-positive and false-negative findings. Another important technological advancement in DBT equipment is the integration of artificial intelligence (AI) and machine learning algorithms. AI-powered image analysis software can automatically detect and highlight suspicious areas on breast images, assisting radiologists in their interpretation and decision-making process. These AI algorithms can also analyze large datasets of breast images to identify patterns and trends, potentially leading to the development of more precise diagnostic tools and predictive models for breast cancer detection.

Also, advancements in ergonomic design and user interface enhancements have made digital breast tomosynthesis equipment more user-friendly and efficient for healthcare providers. Streamlined workflows, intuitive software interfaces, and ergonomic features such as adjustable compression paddles improve the overall user experience and workflow efficiency, enabling radiologists to perform more screenings in less time.

Key Market Challenges

High Initial Setup Costs

One of the primary challenges hindering the adoption of digital breast tomosynthesis equipment is the high initial setup costs associated with acquiring and implementing this technology. Healthcare facilities, particularly in resource-constrained settings, may face budgetary constraints that limit their ability to invest in expensive imaging equipment. The cost of purchasing DBT systems, along with installation, training, and maintenance expenses, can pose a significant financial burden on healthcare providers, impeding the widespread adoption of digital breast tomosynthesis technology.

Reimbursement Issues

Reimbursement policies and coverage for digital breast tomosynthesis procedures vary across different regions and healthcare systems, leading to inconsistencies and uncertainties regarding reimbursement for screening and diagnostic services. In some cases, reimbursement rates may not adequately cover the costs associated with DBT procedures, limiting healthcare providers' incentive to invest in this technology. Additionally, delays or denials in reimbursement approvals can create financial challenges for healthcare facilities, discouraging them from adopting digital breast tomosynthesis equipment.

Regulatory Hurdles

Regulatory approval processes for medical devices, including digital breast tomosynthesis equipment, can be lengthy, complex, and costly. Manufacturers must adhere to stringent regulatory requirements and standards set forth by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure the safety, efficacy, and quality of their products. Delays in obtaining regulatory approvals or compliance with evolving regulatory requirements can significantly impact product launch timelines and market access, posing challenges for manufacturers seeking to introduce new digital breast tomosynthesis technologies.

Key Market Trends

Increasing Adoption of 3D Mammography

The increasing adoption of 3D mammography is a pivotal factor driving the growth of the global digital breast tomosynthesis (DBT) equipment market. 3D mammography, also known as digital breast tomosynthesis (DBT), has emerged as a preferred imaging modality for breast cancer screening and diagnosis due to its superior capabilities compared to traditional 2D mammography.

3D mammography provides a three-dimensional view of the breast tissue, allowing radiologists to examine breast images layer by layer, thereby improving the detection of breast abnormalities, including small tumors and lesions. This enhanced sensitivity and specificity of 3D mammography in detecting breast cancer have led to its widespread adoption among healthcare providers worldwide. The adoption of 3D mammography is driving the demand for digital breast tomosynthesis equipment, as DBT systems are specifically designed to perform 3D mammography imaging. Healthcare facilities are investing in DBT equipment to upgrade their breast imaging capabilities and offer patients access to advanced screening technologies.

Moreover, the clinical benefits of 3D mammography, including improved cancer detection rates and reduced false-positive findings, are driving market growth. Studies have demonstrated that 3D mammography detects more cancers compared to 2D mammography alone while also decreasing the number of false-positive results, leading to more accurate diagnoses and reducing unnecessary follow-up procedures. Regulatory bodies and healthcare organizations are endorsing the use of 3D mammography in breast cancer screening programs, further fueling its adoption. Guidelines from organizations such as the American Cancer Society and the European Society of Breast Imaging recommend the use of DBT as part of routine breast cancer screening for certain patient populations.

Integration with Multimodal Imaging Approaches

The integration of digital breast tomosynthesis (DBT) with multimodal imaging approaches is emerging as a key driver of growth in the global digital breast tomosynthesis equipment market. Multimodal imaging combines the strengths of different imaging modalities, such as ultrasound, magnetic resonance imaging (MRI), and DBT, to provide a more comprehensive evaluation of breast lesions and improve diagnostic accuracy.

By integrating DBT with other imaging modalities, healthcare providers can obtain complementary information about breast tissue morphology, composition, and vascularity, enhancing the diagnostic capabilities of DBT equipment. This integrated approach enables radiologists to better characterize breast lesions, differentiate between benign and malignant lesions, and guide treatment planning.

One of the primary benefits of integrating DBT with multimodal imaging approaches is the ability to overcome the limitations of individual imaging modalities. While DBT excels in detecting architectural distortions and microcalcifications associated with breast cancer, it may have limitations in visualizing certain types of lesions, such as cysts or masses with complex morphologies. By combining DBT with ultrasound or MRI, healthcare providers can obtain additional information about lesion morphology, vascularity, and tissue composition, enhancing diagnostic confidence and reducing the need for additional imaging studies. Multimodal imaging approaches enable more personalized and precise treatment planning for breast cancer patients. By incorporating information from multiple imaging modalities, healthcare providers can tailor treatment strategies based on individual patient characteristics, such as tumor size, location, and histological features. This personalized approach improves treatment outcomes and reduces the risk of undertreatment or overtreatment, leading to better patient care and satisfaction.

The integration of DBT with multimodal imaging approaches also streamlines the diagnostic workflow and improves efficiency in breast imaging centers. Rather than performing separate imaging studies using different modalities, healthcare providers can perform comprehensive evaluations using a single imaging session, saving time and resources for both patients and providers.

Segmental Insights

Product Type Insights

Based on the product type, therapeutics segment emerged as the dominant segment in the global digital breast tomosynthesis equipment market in 2023. This is primarily due to the combined benefits offered by both 2D and 3D mammography technologies, making it a preferred choice among healthcare providers and patients alike. 2D mammography has been the standard screening tool for breast cancer detection for many years, offering reliable results and widespread availability. However, it has limitations, particularly in detecting lesions in dense breast tissue and differentiating between overlapping structures. On the other hand, 3D mammography, or digital breast tomosynthesis (DBT), provides a three-dimensional view of the breast tissue, allowing for better visualization and characterization of breast lesions.

Regional Insights

North America solidified its position as the leading region in the global digital breast tomosynthesis equipment market, capturing the largest market share. This dominance can be attributed to North America's robust healthcare infrastructure, characterized by advanced medical facilities and well-established breast cancer screening programs. With a high level of healthcare expenditure, the region fosters a conducive environment for the adoption of innovative medical technologies, including digital breast tomosynthesis equipment.

Healthcare providers in North America increasingly integrate digital breast tomosynthesis into routine clinical practice, recognizing its effectiveness in detecting breast cancer and reducing false positives. The technology's ability to provide three-dimensional images of the breast improves diagnostic accuracy and enhances the early detection of abnormalities, contributing to better patient outcomes. North America's proactive approach to breast cancer awareness and screening initiatives further drives the adoption of digital breast tomosynthesis equipment. Government-led campaigns and advocacy efforts raise awareness about the importance of early detection, encouraging women to undergo regular screenings with advanced imaging technologies.

Key Market Players

• PerkinElmer Inc. (Dexela Ltd.)
• Hologic, Inc
• GE HealthCare Technologies Inc.
• Fujifilm Holdings Corporation
• Siemens Healthineers
• General Medical Merate SpA (IMS GIOTTO SPA)
• Varex Imaging Corporation
• Trivitron Healthcare
• Metaltronica Spa
• Analogic Corporation

Report Scope:

In this report, the Global Digital Breast Tomosynthesis Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Digital Breast Tomosynthesis Equipment Market, By Product Type:

• Diagnostics
• Therapeutics

Digital Breast Tomosynthesis Equipment Market, By End-User:

• Hospitals
• Diagnostic Centers
• Other End-Users

Digital Breast Tomosynthesis Equipment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Digital Breast Tomosynthesis Equipment Market.

Available Customizations:

Global Digital Breast Tomosynthesis Equipment Market report with the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).